[96a5a0]: / output / allTrials / identified / NCT02825420_identified.json

Download this file

190 lines (190 with data), 7.8 kB

  1
  2
  3
  4
  5
  6
  7
  8
  9
 10
 11
 12
 13
 14
 15
 16
 17
 18
 19
 20
 21
 22
 23
 24
 25
 26
 27
 28
 29
 30
 31
 32
 33
 34
 35
 36
 37
 38
 39
 40
 41
 42
 43
 44
 45
 46
 47
 48
 49
 50
 51
 52
 53
 54
 55
 56
 57
 58
 59
 60
 61
 62
 63
 64
 65
 66
 67
 68
 69
 70
 71
 72
 73
 74
 75
 76
 77
 78
 79
 80
 81
 82
 83
 84
 85
 86
 87
 88
 89
 90
 91
 92
 93
 94
 95
 96
 97
 98
 99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
{
"info": {
"nct_id": "NCT02825420",
"official_title": "NonInterventional, Multicenter, Prospective, European Study to Describe the Effectiveness of Trabectedin + PLD in the Treatment of Relapsed Ovarian Cancer (ROC) Patients According to SmPC Regardless of Previous Use of an Antiangiogenic Drug",
"inclusion_criteria": "* Women aged 18 years or older.\n* Presence of platinum-sensitive relapsed ovarian cancer.\n* Treatment and treated indication according to local label SmPC and reimbursement for trabectedin and PLD treatment.\n* Prior treatment with a minimum of 1 cycle of trabectedin + PLD according to SmPC before inclusion in the study, and no more than 3 previous treatment lines.\n* Written informed consent indicating that patients understand the purpose and procedures and are willing to participate in the study.\nHealthy volunteers allowed\nMust be FEMALE\nMust have minimum age of 18 Years",
"exclusion_criteria": "* None",
"miscellaneous_criteria": ""
},
"inclusion_lines": [
{
"line": "* Women aged 18 years or older.",
"criterions": [
{
"exact_snippets": "Women",
"criterion": "gender",
"requirements": [
{
"requirement_type": "expected gender",
"expected_value": "female"
}
]
},
{
"exact_snippets": "aged 18 years or older",
"criterion": "age",
"requirements": [
{
"requirement_type": "minimum age",
"expected_value": {
"operator": ">=",
"value": 18,
"unit": "years"
}
}
]
}
]
},
{
"line": "* Presence of platinum-sensitive relapsed ovarian cancer.",
"criterions": [
{
"exact_snippets": "Presence of platinum-sensitive relapsed ovarian cancer.",
"criterion": "platinum-sensitive relapsed ovarian cancer",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
}
]
},
{
"line": "* Treatment and treated indication according to local label SmPC and reimbursement for trabectedin and PLD treatment.",
"criterions": [
{
"exact_snippets": "Treatment and treated indication according to local label SmPC",
"criterion": "treatment and treated indication",
"requirements": [
{
"requirement_type": "compliance",
"expected_value": "local label SmPC"
}
]
},
{
"exact_snippets": "reimbursement for trabectedin and PLD treatment",
"criterion": "reimbursement",
"requirements": [
{
"requirement_type": "eligibility",
"expected_value": [
"trabectedin",
"PLD treatment"
]
}
]
}
]
},
{
"line": "* Prior treatment with a minimum of 1 cycle of trabectedin + PLD according to SmPC before inclusion in the study, and no more than 3 previous treatment lines.",
"criterions": [
{
"exact_snippets": "Prior treatment with a minimum of 1 cycle of trabectedin + PLD",
"criterion": "prior treatment with trabectedin + PLD",
"requirements": [
{
"requirement_type": "minimum cycles",
"expected_value": {
"operator": ">=",
"value": 1,
"unit": "cycle"
}
}
]
},
{
"exact_snippets": "no more than 3 previous treatment lines",
"criterion": "previous treatment lines",
"requirements": [
{
"requirement_type": "maximum number",
"expected_value": {
"operator": "<=",
"value": 3,
"unit": "treatment lines"
}
}
]
}
]
},
{
"line": "* Written informed consent indicating that patients understand the purpose and procedures and are willing to participate in the study.",
"criterions": [
{
"exact_snippets": "Written informed consent indicating that patients understand the purpose and procedures and are willing to participate in the study.",
"criterion": "informed consent",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
}
]
},
{
"line": "Healthy volunteers allowed",
"criterions": [
{
"exact_snippets": "Healthy volunteers allowed",
"criterion": "volunteer health status",
"requirements": [
{
"requirement_type": "status",
"expected_value": "healthy"
}
]
}
]
},
{
"line": "Must be FEMALE",
"criterions": [
{
"exact_snippets": "Must be FEMALE",
"criterion": "gender",
"requirements": [
{
"requirement_type": "N/A",
"expected_value": "female"
}
]
}
]
},
{
"line": "Must have minimum age of 18 Years",
"criterions": [
{
"exact_snippets": "minimum age of 18 Years",
"criterion": "age",
"requirements": [
{
"requirement_type": "minimum",
"expected_value": {
"operator": ">=",
"value": 18,
"unit": "Years"
}
}
]
}
]
}
],
"exclusion_lines": [],
"miscellaneous_lines": [],
"failed_inclusion": [],
"failed_exclusion": [
{
"line": "* None",
"criterions": []
}
],
"failed_miscellaneous": []
}